AGO-OVAR 2.21
Trial Description:
A prospective randomized Phase III trial of carboplatin/gemcitabine/bevacizumab vs. carbolatin/pegylated liposomal doxorubin/bevacizumab in patients with platinum-sensitive recurrent ovarian cancer
Lead Cooperative Group:
Trial Number:
Disease Site:
Recurrent Ovarian
Trial Status:
Completed
Contact person:
jpfisterer